Plus, Big Pharma faces up to a patent cliff and Jane Street’s troubles in India
Shares in drugmakers show little reaction to US president’s latest pronouncement
US pharma giant seeks to expand footprint beyond cancer treatment as its biggest product nears patent cliff
President also says he will impose levies of up to 200% on drug imports after a transition period
When blockbuster drugs lose IP protections it can wipe out billions of dollars in revenue for companies
There can be no either/or in mental health — we must rigorously examine pharmaceutical and social solutions
Swiss pharma group says lack of provision for small infants has led to ‘treatment gap’ in deadly disease
Focusing on artificial dyes and seed oils misses the true culprit — excess toxic fat
Issues ranging from medicine approval delays to attacks on Harvard research grants knock driver of regional economy
Drug group chief Pascal Soriot frustrated with UK but shareholders worry about country losing FTSE’s largest company
Ministers remain locked in talks with sector over future of clawback tax
The US appears to be turning its back on a scientific consensus that has relegated several diseases to history
Mebufotenin benzoate also requires a much shorter period of clinical supervision in trial
Research offers clues to choosing chemotherapy treatments with fewer long-term side effects
For TV network operators, the prognosis looks glum
Oxford research shows adjuvant chemicals included in vaccinations may enhance their antiviral effect
The decline in funding for vaccinations poses a worldwide threat
And who could have anticipated this turn of events apart from literally anyone?
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments
US president’s ‘most favoured nation’ policy could also lead to European patients losing access to new treatments
Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target
Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose
$140mn financing will allow Draig Therapeutics to move drug candidates into clinical trials
Commissioner says agency is hiring scientists as industry warns over delays
